FDA approves at-home starter dose of Eisai-Biogen Alzheimer’s drug

FDA clears at-home start dose for Alzheimer's drug Leqembi

FDA clears at-home start dose for Alzheimer's drug Leqembi Phil.Taylor Tue, 14/07/2026 - 08:36

<![CDATA[FDA Approves At-Home Starting Dose of Lecanemab for Treatment of Alzheimer Disease]]>

Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi

Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in t

Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik

Related Stocks: BIIB

Biogen defends anti-tau drug after stock slides on Alzheimer’s readout

Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d